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ABSTRACT Mesenchymal stromal cells (MSCs) are adult multipotent stem cells residing as pericytes in various tissues and organs where they
can differentiate into specialized cells to replace dying cells and damaged tissues. These cells are commonly found at injury sites
and in tumors that are known to behave like “wounds that do not heal.” In this article, we discuss the mechanisms of MSCs in
migrating, homing, and repairing injured tissues. We also review a number of reports showing that tumor microenvironment
triggers plasticity mechanisms in MSCs to induce malignant neoplastic tissue formation, maintenance, and chemoresistance, as
well as tumor growth. The antitumor properties and therapeutic potential of MSCs are also discussed.
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Introduction
Mesenchymal  stromal  cells  (MSCs)  are  immature,  adherent
stromal cells residing in various tissues and organs, including
bone  marrow  (BM-MSCs),  adipose  tissue  (AT-MSCs),
umbilical  cord  blood,  and  placenta.  The  presence  of
circulating  MSCs  in  the  peripheral  blood  is  still  debated1,2.
MSCs  divide  into  daughter  cells  that  share  the  same
properties  of  their  mother cell  (self-renewal)  or differentiate
into  specialized  cells  to  replace  dying  cells  and  repair
damaged tissues (multilineage differentiation). Notably, these
adult stem cells can differentiate into various cell types of the
mesodermal  lineage,  including  chondrocytes,  osteoblasts,
adipocytes, endothelial cells,  and myocytes3;  moreover, non-
mesodermal differentiation into neural, liver, pancreatic, and
gastric cells has been reported in vitro, but this phenomenon
occurring  in  vivo  has  not  been  proven4-7.  MSCs  express
membrane  CD90,  CD73,  and  CD105,  and  are  negative  for
CD45, CD34, CD31, CD14, CD19, and HLA-DR3,8.
Emerging  data  suggest  that  MSCs  can  promote
tumorigenic processes, including malignant transformation,
establishment and maintenance of cancer cells, promotion of
angiogenesis and neovascularization-sustaining neoplastic
tissues,  metastasis  formation,  and  chemoresistance  to
anticancer drugs9-11. MSCs have the capability to contribute
to  the  formation  of  cancer  stem  cell  niche  and  support
stemness9-11. In this article, we provide an overview on the
MSC properties that drive their tissue repair capability, such
as  migration,  adhesion,  differentiation,  growth  factor
production, and immune regulation. Then, we discuss how
the same features may boost tumor development and favor
chemoresistance mediated by the tumor microenvironment.
MSCs, regenerative medicine, and
cell therapy
Therapeutic potential of embryonic and adult
stem cells
Tissue or organ transplantation is still associated with various
issues, including inadequate donor availability, compatibility
between donors and recipients, and risk of developing graft-
related complications. Stem cell transplantation has emerged
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as  a  promising  strategy  to  replace  or  improve  organ
transplantation12,13.  The  premise  is  that  stem  cells,  once
administered  to  the  recipient  with  organ  failure,  migrate  to
the  damaged sites  and differentiate  into  the  specific  affected
cell types to restore/replace damaged tissues and rescue organ
functions.  Stem  cells  can  be  classified  as  embryonic  stem
cells,  which give rise  to all  tissue types,  and adult  stem cells,
which  are  involved  in  the  tissue  homeostasis  by  replacing
senescent  or  damaged  cells  based  on  their  differentiation
potency and developmental hierarchy. The high proliferation
rate  and  pluripotency  of  embryonic  stem  cells,  that  is,  the
ability to differentiate into virtually all cell types of the three
germinal  layers  (ectoderm,  mesoderm,  and  endoderm),
would make them the optimal model  for tissue engineering,
regardless of their potential immunogenicity. However, their
therapeutic  use  is  entangled  with  critical  ethical  issues  and
uncontrolled proliferation, leading to teratoma formation in
vivo;  moreover,  the  latter  issue  remains  unsolved  even  with
the  use  of  alternative  technologies  aimed  at  achieving
embryonic  stem  cell-like  cells,  such  as  induced  pluripotent
stem  cells14,15.  Consequently,  adult  stem  cells  have  rapidly
become  the  main  tool  in  regenerative  medicine  and  tissue
engineering  because  of  their  high  proliferative  and
differentiation  properties,  easy  collection,  and  weak  im-
munogenicity16-20.
MSC therapeutic potential
MSC use is  a first  attempt in adult stem cells-based therapy.
A  body  of  evidence  from  in  vivo  and  in  vitro  studies  shows
that  MSCs  possess  regenerative  potential  associated  to  their
adhesion,  migration,  proliferation,  differentiation,  and
immunosuppression properties21-24. This adult stem cell type
is highly used in preclinical studies and phase 2 and 3 clinical
trials  aimed  at  mitigating  graft-versus-host  disease  (GvHD)
and  at  regenerating  damaged  tissues  in  many  diseases  and
conditions  that  are  thought  to  originate  from  deleterious
damages  to  tissues16,25.  Examples  include  the  attempts  to
regenerate bone, heart, muscle, and nervous tissues following
tissue  injury  from  inflammation-  and  oxidative  stress-
associated  pathogenic  processes26,27.  Tissue  repair  and
attenuation of chronic or acute inflammation were observed
after  local  or  systemic  infusion  of  MSC  in  patients16,25.
However,  the  real  clinical  impact  of  this  cell  therapy
approach remains unknown and requires further multicenter
studies  based  on  standardized  methods  to  assess  safety  and
efficacy.
MSCs have been well characterized with respect to their
ability to produce a range of growth factors and cytokines,
which inspired the designation of these cells as an “injury
drugstore”28.  Notably,  MSC secretome screening revealed
numerous growth factors that potentially contribute to tissue
repair, such as (i) vascular endothelial growth factor (VEGF),
which  has  angiogenic  abilities  and  triggers  endothelial
differentiation  in  MSCs  through  VEGFR-2/Sox1829  and
Rho/myocardin-related  transcription  factor-dependent
mechanisms, thereby promoting blood vessel repair30,31; (ii)
hepatocyte growth factor (HGF) that may play a role in MSC
regenerative  effects  on  the  liver,  as  it  promotes  the
differentiation and proliferation of  hepatic-like  cells  and
induces MSC-associated cytoprotective effects on hepatocytes
in vivo32-34; (iii) transforming growth factor-beta (TGF-β),
whose  involvement  was  reported  in  MSC-mediated
heart  repair,  where  it  stimulated  the  differentiation  of
cardiomyocytes  and  promoted  angiogenesis35 ;  (iv)
angiopoietin-1, another pro-angiogenic factor involved in
MSC-mediated improvement of cardiac function (36) and
skin  damage37;  (v)  epidermal  growth  factor  (EGF)  that
mediates MSC-associated protection of podocytes from high
glucose-induced apoptosis38;  (vi)  platelet-derived growth
factor (PDGF), whose release by MSCs was reported to play a
role in cardiac healing after myocardial injury by exerting a
pro-migratory effect on resident cardiac stem cells39;  (vii)
granulocyte-colony  stimulating  factor  (G-CSF),  whose
release by MSCs is  triggered by co-cultures with counter-
inflammatory or tissue repair macrophages, enhanced by the
MSC  cartilage-forming  capacity40;  and  (viii)  fibroblast
growth factor (FGF), and cytoprotective factors that partly
account for the therapeutic effects of MSCs in lung diseases41.
Numerous other soluble factors are released by MSCs and
contribute to the properties of these cells, including stem cell
factor, MCP-3, CXCL8, CXCL9, CXCL16, CCL20, CCL25,
IL-6, and IL-1242-45.
MSC properties contributing to tissue repair
ability
Migration and homing
Determinant  factors  of  cell  therapeutic  potential  include
migration, homing, and survival when administered through
a  specific  route.  Labeling  and  tracking  of  MSCs  have  been
employed  to  understand  the  MSC  distribution  in  the  body
following  local  or  systemic  injection.  Reported  labeling
approaches include intracellular magnetic contrast materials,
radioactive  compound,  and  fluorescent  dyes46-48;  and
expression  systems,  such  as  luciferase,  green  fluorescent
protein (GFP), and Alu sequences48-52. Studies addressing the
final location of MSCs after systemic infusion in disease-free
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laboratory animals revealed that injected MSCs could localize
in  diverse  sites  of  organs,  such  as  the  lung,  liver,  and
spleen53,54.  Interestingly,  comparable studies in animals with
damaged  organs  revealed  a  tropism  of  injected  MSCs  for
damaged  sites,  particularly  following  administration  at
neighboring  areas.  For  instance,  Barbash  and  colleagues54
reported  that  99mTc-exametazime-labeled  MSCs  infused  in
the left ventricle cavity, instead of intravenously, resulted in a
drastically  reduced  lung  uptake  and  increased  infarcted
myocardium  uptake  in  a  rat  model.  Comparably,  after
palatine  tonsil  MSCs  (T-MSCs)  were  intravenously
administered  to  carbon  tetrachloride-induced  mouse  model
of  liver  fibrosis,  the  T-MSCs  were  only  found  in  the  liver55.
Intravenously  injected  MSCs  migrated,  distributed  to  the
colon, and effectively mitigated disease severity indicators in
a  rat  model  of  ulcerative  colitis  via  an  anti-inflammatory
effect  partly  mediated  by  G-CSF56.  Moreover,  nasal  mucosa
ecto-mesenchymal  stromal  cells  injected  in  the  tail  vein
migrated  to  the  inflammation  sites  and  suppressed
eosinophils and sneezing in a mouse model of allergic rhinitis
via  downregulation  of  Th-2  cell  secretory  activity,  that  is,
decreases  in  IgE,  IL-4,  IL-5,  and  IL-10  secretions;  and
upregulation  of  Th-1  cell  secretion,  including  the  release  of
IgG2  and  IFN-γ57.  Interestingly,  MSC  delivery  into  the
arterial  system  via  injection  into  the  aortic  arch  or  tail  vein
supports  the  “first-pass”  cell  delivery  hypothesis.  Indeed,
MSCs  showed  significant  entrapment  in  the  lungs  when
delivered  intravenously  into  the  tail  vein.  However,  when
delivered  intra-arterially  through  the  aortic  arch,  the  cells
were  highly  and  evenly  distributed  in  the  entire  animal45.
MSCs  were  reported  to  home  at  the  sites  of  ischemia,
hypoxia,  inflammation,  and  other  injuries54,55,58.  Overall,
such  sites  have  high  concentrations  of  pro-inflammatory
cytokines,  chemokines,  and  soluble  factors  that  may  attract
MSCs and favor their homing21,22.
The migration and homing of infused MSCs to damaged
tissues  are  important  parameters  to  consider  for  clinical
purposes. Failure or poor results following attempts of MSC-
based therapy observed in a significant number of patients
raised at least three concerns. First is their overall viability
following  infusion  via  the  route  used  (local  versus
systemic43); moreover, despite clinical evidence and reports
from experimental models supporting the assumption that
MSC homing may be governed by damaged tissues, MSCs
can still be found in unwanted sites, thereby raising safety
concerns for the long-term effects of MSC-based therapy59,60,
particularly  in  pediatric  patients61-63.  Second  is  the  en-
graftment degree of MSCs in targeted tissues, and the third,
as  a  consequence,  is  the  fate  of  these  cells  if  improperly
engrafted.  Improving  the  MSC  viability  and  therapeutic
potency is currently a challenge. A remarkable example is
provided by MSC-based therapy in lung diseases, where MSC
grafting and homing to affected tissues are successful. This
therapeutic approach has been held back by the difficulty of
engrafted  MSCs  to  survive  more  than  one  week  after-
transplantation  in  hostile  microenvironments41.  Similar
observations have been reported in other injuries, including
renal  ischemia/reperfusion  injury,  where  hypoxia
preconditioning of MSCs appeared as a possible solution64.
Hypoxia  induces  the  secretion  of  anti-inflammatory,
antiapoptotic,  and  anti-fibrotic  factors,  as  well  as  the
expression of cytoprotective genes, thereby enhancing the
therapeutic potential and survival duration of the engrafted
MSCs41,64. Recently, a study in human umbilical cord MSCs
suggested the three-dimensional spheroid culture of these
stem cells as a strategy to promote cell yield and stemness
maintenance65.
Moreover, functional differences were reported in MSCs
from  human  dental  pulp  and  periodontal  ligaments66,
indicating that MSCs from topographically related tissues do
not  necessarily  share  identical  properties,  thereby
emphasizing  the  need  for  comparing  the  multipotency,
immunosuppression  properties ,  response  to  pro-
inflammatory  cytokines,  and eventually  the  secretome of
MSCs from diverse sources before clinical use. Reports in
various  human  studies21,22  and  animal  models23,24  cor-
roborated these observations.
Differentiation and transdifferentiation
The differentiation ability of MSCs accounts for their positive
effects  in  diseases  wherein  pathogenic  processes  include
severe tissue damage, such as in cardiac lesions. For instance,
a  promising  observation  in  MSC-mediated  therapy  was  the
finding that injecting MSCs in an infarcted heart generates a
new  tissue  made  up  of  proliferating  myocyte  and  vascular
structures67. In a study with enhanced-GFP-labeled MSC, the
regenerated  cardiomyocytes,  vascular  smooth  muscle,  and
endothelial  cells  were  EGFP+,  suggesting  that  the  new heart
tissue  was  mainly  derived  from  MSC  differentiation68.  In  a
study where  the  injection of  GFP-labeled AT-MSC in spinal
cord of a canine model of acute spinal injury was associated
with  a  functional  recovery,  GFP-positive  cells  at  the  injury
site included cells positive for GFAP (astrocyte marker), Tuj-
1,  and  NF160  (markers  of  immature  post-mitotic  neurons),
suggesting that functional improvement was mediated by the
differentiation  of  AT-MSCs  into  functional  astrocytes  and
neurons69.
The plasticity of  MSCs does not derive only from their
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ability to differentiate into other cell types (cell replacement),
but includes fusion with resident cells, thereby resulting in
the  emergence  of  new  cells  capable  of  tissue-specific
functions. This fusion is termed as lineage reprogramming or
transdifferentiation.  MSC  transdifferentiation  results  in
phenotypes that are highly related to resident cells70,71. Many
studies report  MSC ability to fuse with various cell  types.
Examples  of  such  cell  types  include  cardiomyocytes72,73,
hepatocytes74,75,  neurons,  and  corneal  cells76,77.  The
increasing number of reports suggests that cell fusion is an
alternate and a common and probably pivotal pathway in
MSC plasticity.
Immune modulation
Besides  the  classic  cell  replacement  (differentiation)  and
reprogramming  (transdifferentiation)  paradigms,  immune
modulatory  properties  contribute  to  the  benefits  of  MSC
therapy.  MSCs  may  modulate  immune  responses  using
paracrine  mechanisms  and  cell-cell  interaction.  Studies
suggesting  that  the  activating  properties  in  MSCs  are  scarce
include reports of the ability of MSC to activate allogeneic T-
cells  in  mixed  leukocyte  reaction78,  stimulate  the  activation
and proliferation of resting T-cells in co-cultures79, the MSC
behavior  as  conditional  antigen  presenting  cells  (APCs)  in
syngeneic  immune  responses80,  the  TLR-activated  MSC
ability  to  recruit  and  activate  immune  inflammatory  cells81,
and  the  secretion  of  pro-inflammatory  cytokines  and
chemokines  by  MSCs42,44,45.  However,  the  clinical
implications of these observations are still unclear.
The  immunosuppressive  properties  of  MSCs  are  well
documented.  These  effects  may  emerge  from  cell-cell
interactions with both innate and adaptive immune system
cells82-85,  partly  mediated  by  Toll-like  receptor  (TLR)
pathways, as revealed by the immunosuppression effects of
TLR4 activation (via mechanisms involving VCAM-1- and
ICAM-1-mediated  binding  of  immune  cells)  and  TLR3
activation (via  mechanisms that  induce  the  formation of
cable-like  hyaluronic  acid  structures)86,87.  The  immu-
nosuppressive abilities of MSC can be mediated by the release
of  soluble  factors  with  anti-inflammatory  effects,  like
indoleamine 2, 3-dioxygenase (IDO), inducible nitric oxide
synthase  (iNOS),  prostaglandin  E2  (PGE2),  G-CSF,  and
TGF-β40,56,88-90. Such immunosuppressive effects account for
the ability of MSC to inhibit inflammatory responses that are
induced  by  the  presence  of  transplanted  tissues,  thereby
decreasing the probability of rejection91-95. MSCs prevents
autoimmunity via CCL2-dependent recruitment of myeloid-
derived suppressor cells, in a mouse model of experimental
autoimmune uveitis96.
Clinical  application of MSCs requires a relatively long-
term ex vivo  culture that results in cellular senescence and
reduced  therapeutic  activity  of  transplanted  cells97.
Experimental evidence shows that the therapeutic potency of
MSCs may be enhanced and even restored by improving the
immunosuppressive properties of these cells. For instance, in
a  recent  study,  these  properties  were  improved  by  using
vitamin D receptor agonists as additives in a mouse model of
sterile kidney inflammation98. This approach resulted in the
suppression of Th17 and related inflammatory responses in
the  kidney.  In  another  study,  the  MSC-activating
neuropeptide, termed as substance P, potentiated the ability
to secrete TGF-β1 in long-term culture MSCs, indicating a
recovery of their immunosuppressive function97. Moreover,
these cells recovered their ability to inactivate CD4+ cells in
co-cultures (cell-cell  contact).  Adenoviral transduction of
MSCs  was  proposed  as  a  strategy  for  increasing  the
immunosuppressive properties of engrafted MSCs after cell
transplantation66.  Overall,  because  of  their  immune
modulatory features, MSC are being tested to treat immune
disorders,  such  as  GvHD,  rheumatoid  arthritis,  multiple
sclerosis, type 1 diabetes, and inflammatory bowel disease,
and to enhance transplant tolerance45.
MSCs and tumor microenvironment
MSC plasticity and tumorigenesis
A major role for MSCs in cancer development emerged from
the fact that MSCs are commonly found in stromal niches of
various  tissues  undergoing  tumorigenesis,  including  bone
marrow  in  hematological  malignancies9-11,  and  in  the
affected  ducts  and  lobules  of  breast  cancer99-101.  Moreover,
MSC  research  insights  raised  concerns  about  the  possibility
of their role in all  the developmental and maintenance steps
of  malignant  tumors  from  initiation  until  the  metastatic
spread.  Growing evidence  supports  the  idea  that  MSCs may
exploit  the  properties  related  to  tissue  repair  to  promote
tumorigenesis  and  protect  transforming  cells  from
chemotherapy10,83,102-109.  Therefore,  events  and  mechanisms
accounting for MSC-mediated tissue regeneration and repair,
such  as  MSC  activation,  mobilization,  migration,  and
homing  to  stromal  microenvironment,  differentiation  and
transdifferentiation,  as  well  as  the  secretion  of  cytokines,
growth  factors,  and  other  soluble  factors  modulating  the
local immune responses and improving stromal cell survival,
may  support  the  pro-oncogenic  role  of  MSCs.  Thus,  MSCs
may  eventually  facilitate  cancer  cell  growth,  partly  by
favoring the angiogenic and neovascularization processes that
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allow the survival of malignant neoplastic tissues107-109 and by
modulating anticancer immunity and hijacking immune cells
to  favor  tumor  invasion  and,  subsequently,  metastatic
processes99,103-105,110.  These  findings  have  tempered  the
enthusiasm  over  the  clinical  application  of  stem  cells  and
further  raised  safety  concerns  of  the  long-term  use  of  these
cells  and  which  categories  of  patients  may  be  suitable  for
MSC-based therapies.
Tumor stroma recapitulates damaged tissue
microenvironment
MSC plastic properties generate pro-tumoral
stroma
Tumor  stroma  mainly  include  immune,  endothelial,  and
immune  cells,  such  as  lymphocytes,  macrophages,
neutrophils,  and  natural  killer  cells,  as  well  as  adipocytes,
myofibroblasts,  and  carcinoma  associated  fibroblasts
(CAFs)111.  Among  the  most  abundant  tumor  stroma
components, CAFs considerably boost tumor growth, induce
epithelial-mesenchymal  transition,  promote  the  acquisition
of  invasive  phenotypes,  and  support  angiogenesis112-115.
Moreover,  CAFs  could  induce  epithelial-mesenchymal
transition through paracrine TGF-β signaling115.
Besides, early in vitro studies revealed that, following long
treatments  with tumor cell-conditioned medium in  vitro,
MSCs can differentiate into CAFs116  via a TGFβ1/Smad3-
dependent mechanism117,118. Growing evidence supports the
ability  of  the MSC to differentiate  into CAFs in  vivo.  For
instance, MSCs differentiate into CAFs to promote metastatic
tumors in advanced solid cancers118-124. Moreover, MSCs in
tumors  may  display  transdifferentiation,  wherein  fusion
occurs with resident cells, such as malignant cells and other
components of the tumor stroma, thereby resulting in the re-
modeling of the tissue stroma of the affected organ into a
pro-tumoral  stroma103,107,125-127 .  Examples  of  MSC
transdifferentiation  include  MSC  fusion-induced  re-
programming in lung cancer127, human melanoma107, breast
cancer, and ovarian adenocarcinoma cells126. These reports
further suggested that the plastic role of  MSCs is  a major
pathogenic step because it  drives the generation of a pro-
tumoral stroma.
Homing: MSCs exhibit tropism for tumors
Tumors  behave  like  “wounds  that  do  not  heal”,  and
recapitulate  most  of  the  characteristic  events  of  damaged
tissue  (wounding)  microenvironment,  such  as  hypoxia,
mechanical  stress,  sustained  inflammation,  and  increased
oxidative/nitrosative  stress50,111.  Numerous  studies  reported
tumor microenvironment tropisms of  both endogenous and
exogenous  MSCs.  For  instance,  in  a  study  where  MSCs
labeled  with  firefly  luciferase-enhanced  GFP  (fLuc-eGFP)
reporter  gene  were  intravenously  injected  to  subcutaneous
and  lung  metastasis  mouse  models,  the  injected  MSCs
survived,  proliferated,  and  differentiated  in  tumor  sites  but
not anywhere else50, thereby suggesting that exogenous MSCs
are disease responsive.
Various soluble molecules have been reported to play a
role in the mobilization or recruitment of MSCs to tumor
sites; however, the major players are the immunoregulatory
cytokine TGF-β40,56,88-90, stromal cell-derived factor 1, also
known  as  C-X-C  motif  chemokine  12  (CXCL12),  and
CXCR4, its receptor that is abundantly secreted by tumor
cells118,121-124,128.  Specifically,  experimental  evidence  has
established  the  CXCL12/CXCR4  pathway  as  a  pivotal
pathway for MSC and malignant cell migration and homing.
Examples include reports suggesting the following: (i) MSC
tumor tropism is mediated by matrix metalloproteinase-1 via
a mechanism dependent on cross-talk with CXCL12/CXCR4
axis129  (129);  (ii)  CXCL12 is  abundantly released by BM-
MSCs and drives the homing of leukemic cells in the bone
marrow  stroma  in  pediatric  precursor  B-cell  acute
lymphoblastic leukemia130; and (iii) CXCL12/CXCR4 signals
the silencing results in the inhibition of MSC migration to
the primary tumor and metastasis sites in solid cancers, such
as breast carcinoma119,120.
MSC paracrine activity controls stromal
component production and immune response
MSCs  and  derived  tumorigenesis-favoring  cells,  such  as
CAFs,  control  the  production  of  stromal  components  and
may  sustain  the  maintenance  of  cancer  cells10,11,99.  For
instance,  MSCs  regulate  chemotaxis,  activation,  function,
and  survival  of  neutrophils  via  an  IL-6-STAT3-ERK1/2
signaling  cascade  in  gastric  cancer  and  related  solid
cancers99,131.  These  MSC-primed  neutrophils  promote  the
differentiation  of  normal  MSCs  into  CAFs131.  Furthermore,
MSCs  promote  angiogenic  processes  that  result  in  blood
vessels  sustaining  neoplastic  tissue  through  its  paracrine
activity.  The  proangiogenic  molecules  released  include  IL-6,
endotheline-1, VEGF, and FGF4132,133.
Unlike injured sites where tissue repair is promoted84-87,133
and in organ transplant  settings  where  the  probability  of
rejection of transplant tissues is  decreased94,95,103,  the im-
munosuppressive  action  of  MSCs  may  result  in  the
suppression of cancer immunity in tumors, enabling cancer
cells to escape immune surveillance. As observed in tissue
repair  processes,  MSCs  can  influence  almost  all  the
Cancer Biol Med Vol 14, No 2 May 2017 133
components  of  the  immune  system  to  attenuate
inflammation and control immune response by interfering
with various immune phenomena, such as cytokine secretion
and the cytotoxicity of T- and NK cells, B-cell maturation
and antibody secretion, and APC maturation, activation, and
function102,134,135.  Moreover,  the  MSC-mediated  im-
munosuppression in the tumor stroma is partly triggered via
paracrine  activity.  Immunosuppressive  properties  appear
when MSCs and CAFS are involved in cell-cell interaction
with  immune  cells,  released  by  the  anti-inflammatory
cytokine  TGF-β,  or  are  stimulated  by  proinflammatory
cytokines, such as TNF-α and IFN-γ40,56,88-90. For example,
the in vitro immunosuppressive properties of MSCs towards
NK, T, and B cells are triggered by the stimulation of MSCs
in TNF-α  and IFN-γ  treatments. Such stimulation enables
MSCs to produce molecules, such as PGE2, iNOS (mouse),
or IDO (human)96-98. Notably, some of these products (that
is,  chemokines and PGE2) can attract immune cells136-138,
whereas  others  (that  is ,  iNOS  and  IDO)  induce
immunosuppression40,56,88-90.
Moreover, damaged tissues and tumor microenvironments
are  rich  in  soluble  factors  belonging  to  the  secretome of
MSCs that can favor tumorigenic processes, such as IL-1, IL-
17, IL6, IFN-γ, TNF-α, Wnt, and Jagged135,36,39-41,139. These
factors  can  induce  profound  changes  in  the  capacity  for
MSC,  drive  its  differentiation  into  CAFs111,114,115,  and
produce  growth  factors29,35,39  and  angiogenic112,115  and
metastatic cytokines118-121. These findings suggest that MSCs
may  participate  in  the  pathogenic  vicious  cycle  wherein
tumor cells modify stromal cells, and in turn, MSCs promote
malignant cell maintenance and tumor growth via plastic and
biochemical changes in the tumor microenvironment (Figure1).
MSC homing to tumors: pro- or
antitumor action?
Discrepancies in antitumor and tumor-
promoting roles of homing MSCs
Conflicting  data  and  concepts  about  antitumor  and  tumor-
promoting  roles  of  MSCs  have  been  reported.  Most  reports
suggest the tumor-promoting roles of MSCs. Gastric cancer-
derived MSCs can prompt gastric cancer progression through
secretion  of  CXCL8140  and  PDGF141.  In  another  recent
report,  BM-MSCs  protected  primary  B  cell  precursor  acute
lymphoblastic  leukemia  cells  from  p53  accumulation  and
subsequent  apoptotic  cell  death  via  a  PGE2-dependent
mechanism142,  suggesting  that  MSCs  protect  cancer  cells
from external  aggression and confer  chemoresistance10,83,102.
Cross-talk between MSCs and tumor cells allows the latter to
escape  from  apoptosis  induced  by  chemotherapy  drugs,
suggesting that an enhanced understanding of such cross-talk
could  reveal  improved  targets  for  progressing  classical
therapies.  Evidence-based  reported  mechanisms  accounting
for the protective interaction between MSCs and tumor cells
include  the  activation  of  developmental  pathways,  such  as
Wnt,  notch,  sonic  hedgehog,  TGF-β,  and  MAPK83,102-105,  as
well as cell adhesion and growth factors10,107-109,143. Inhibiting
these  factors  improves  treatments  using  classical  che-
motherapy  agents.  When  MSCs  were  cultured  with  B-ALL
and  CLL  cells  in  presence  of  notch-blocking  antibodies  or
pan  notch  inhibitors,  like  gamma-secretase  inhibitors,  the
resistant  leukemic  cells  were  sensitized  to  drug-induced
apoptosis,  even  in  the  presence  of  MSCs83,102.  Similarly,  the
inhibition  of  hedgehog144  or  Wnt103  signaling  on  MSCs
enhanced  the  sensibility  of  tumors  to  classical  chemo-
therapies.
The anticancer properties of MSCs have been reported,
particularly the attractive MSC potential for gene or drug
delivery in cancer therapy that has emerged from the cancer
tropism of these cells145,146. For instance, targeted inhibition
of osteosarcoma tumor growth by BM-MSCs expressing the
suicide  gene  therapy  system  cytosine  deaminase/5-
fluorocytosine  was  reported  in  tumor-bearing  mice145.
Human AT-MSCs inhibited human melanoma cell growth in
a conditioned medium, and a reduction in tumor size was
observed in athymic mice when MSCs were injected in the
tissues  surrounding  the  tumor147.  The  antitumor  role  of
MSCs  was  suggested  by  studies  aimed  at  developing  a
traceable therapeutic strategy for treating breast cancer using
MSCs148,149.
MSCs  can  induce  cancer  cell  survival,  stemness,  and
chemoresistance by differentiating into cancer-associated
fibroblasts  (CAFs)  using  a  tumor  growth  factor  β  type  1
(TGFβ1)-dependent mechanism, and by releasing soluble
factors that favor angiogenesis and immunosuppression in
the  tumor  microenvironment,  such  as  prostaglandin  E2
(PGE2)  and  vascular  endothelial  growth  factor  (VEGF).
MSCs can mediate anti-cancer effects by releasing anti-cancer
factors,  such  as  tumor  necrosis  factor-related  apoptosis-
inducing ligand (TRAIL), via mechanisms that are not well
understood.
Factors accounting for MSC ability to play
both tumorigenic and anti-tumorigenic roles
Factors accounting for the ability of MSCs to play both pro-
and  anti-tumorigenic  roles  in  tumor  microenvironment  are
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complex.  These  factors  include  MSC  source,  secretome,
nature  of  interactions  with  cancer  and  host  immune  cells,
type of cancer and cancer cell lines, and specific in vivo or in
vitro  condition7,146,150,151.  Notably,  MSC-secreted  tumor
necrosis  factor-related  apoptosis-inducing  ligand  (TRAIL)
was  reported  as  a  major  promoter  of  MSC  pro-apoptotic
properties on tumor cells150,151, but its expression patterns in
MSCs  and  cancer  models  has  not  been  extensively
investigated146. Consequently, data on the precise conditions
of release of TRAIL and, thus, on the therapeutic relevance of
the  release  induction  by  MSCs  in  tumors,  are  poorly
understood,  despite  recent  reports  suggesting  that  MSC-
released  TRAIL  promotes  apoptosis  even  in  resistant  solid
cancer cells150,151.
Moreover, concerning the origin of MSCs, several studies
have been designed involving MSCs originating from healthy
donors and are functionally different from cancer patients’
MSCs  that  have  undergone  deep  cellular  and  molecular
changes in the tumor stroma, following direct interaction
with tumor cells111,114,115 or exposure to soluble molecules
secreted by the microenvironment112-115,121. Consequently,
MSCs  from  tumors  could  promote  cancer  progression
mainly  by  secreting  soluble  factors  and  increasing  the
number of cancer-promoting stem cells  in the tumor mi-
croenvironment152-154.  Moreover,  short-term memory  of
environmental  stimuli  and  danger  signals  were  recently
reported in MSCs7,  thereby increasing the complexity for
predicting MSC responses in a specific environment.
Finally,  discrepancies  in  available  data  emerged  from
changes in MSC properties when moving from in vitro to in
vivo contexts155. Moreover, in a number of studies, cellular
events  that  are  considered  as  unequivocal  indicators  of
antitumor or  tumor promoting effect  are  insufficient  for
such conclusion. For instance, co-culture of leukemic cells
with  MSCs  can  induce  growth  arrest  of  leukemic  cells;
however, this cannot be always considered as an anticancer
effect  because  cell  quiescence is  a  well-known strategy of
leukemic  stem  cells  that  allow  them  to  escape  from
chemotherapeutic agents that target rapidly dividing cells156.
Conclusions
The multipotency and the ability of  MSCs to secrete soluble
factors  that  induce  immunosuppression  and  favoring
angiogenesis  confer  to  these  stem  cells  the  ability  to  repair
injured tissues. The specific tropism of these cells allows them
to migrate and home into injured tissues to repair them and
induce  immunosuppression,  resulting  in  the  prevention  of
transplant-related  immunity.  These  properties  are  the  basis
for  the  large  use  of  MSCs  in  regenerative  medicine,  tissue
engineering,  and  organ  transplantation.  However,  clinical
and  experimental  bodies  of  evidence  show  that  MSCs  are
chemically  attracted  by  tumors.  In  this  context,  the  plastic
properties  of  MSCs  favor  tumorigenesis;  as  soluble  factors,
 
Figure 1   MSC role in tumor microenvironment. MSCs can induce cancer cell survival, stemness, and chemoresistance by differentiating
into cancer-associated fibroblasts (CAFs) using a tumor growth factor β type 1 (TGFβ1)-dependent mechanism, and by releasing soluble
factors that favor angiogenesis and immunosuppression in the tumor microenvironment, such as prostaglandin E2 (PGE2) and vascular
endothelial growth factor (VEGF). MSCs can mediate anti-cancer effects by releasing anti-cancer factors, such as tumor necrosis factor-
related apoptosis inducing ligand (TRAIL), via mechanisms that are not well understood.
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they  favor  cancer  cell  maintenance,  proliferation,  che-
moresistance,  and suppress anticancer immunity.  Moreover,
MSC  fusion  with  cancer  cells  and  the  tumor  micro-
environment  drive  MSC  differentiation  into  CAFs,  thereby
favoring  tumorigenesis  and  soluble  factor  release.  Never-
theless,  many  studies  showed  that  MSCs  release  potent
anticancer  molecules  in  the  tumor  microenvironment.
Characterization of the mechanisms that drive the release of
such molecules  may give  the  cue  for  anticancer  strategies  to
re-sensitize  and  induce  apoptosis  in  previously  chemo-
resistant cancer cells.
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